{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T16:45:07Z","timestamp":1788626707719,"version":"build-2803163510"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Risk modelling analysis of DEPICT trials show that dapagliflozin reduced estimated cardiovascular and kidney disease risk in T1D persons.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Greatest reduction in estimated ESKD risk was accompanied by an expected rise in eGFR, after 4 weeks post drug discontinuation.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Dedicated outcome trials with SGLT2 inhibitors are warranted in T1D persons with CKD or CVD for best determination of efficacy and risks.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve glycemia and reduce insulin requirements in type 1 diabetes (T1D) and type 2 diabetes. Although SGLT2 inhibitors lower cardiovascular disease (CVD) and ESKD risk in type 2 diabetes, no dedicated cardiorenal outcome trials in T1D have been conducted to date. Using validated risk prediction models, this study evaluated the effect of SGLT2 inhibition on estimated CVD and ESKD risk in a T1D cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Demographics, medical history, and biomarkers were extracted from 1473 participants with T1D enrolled in the Dapagliflozin Evaluation in Patients with Inadequately Controlled Type -1 and -2 trials. Data at baseline, 24, 52, and 56 weeks (4 weeks after drug cessation) were used to estimate 10-year CVD and 5-year ESKD risk using the Steno T1 Risk Engine (SRE) and Scottish Diabetes Research Network (SDRN) risk prediction models. Risk reduction was determined on the basis of relative change in risk from baseline between participants receiving dapagliflozin (pooled 5 and 10 mg) versus placebo. Subgroup analyses were conducted by age, sex, diabetes duration, CVD risk, and CKD status at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The relative change in 10-year estimated CVD risk (SRE: \u20136.50% [\u20138.04% to \u20134.95%] and SDRN: \u20136.77% [\u20138.40% to \u20135.13%]; all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and 5-year ESKD risk (SRE: \u20134.48% [\u20137.68% to \u20131.28%];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006) were lower at the end of 24 weeks of dapagliflozin treatment compared with placebo. Furthermore, the greatest relative change in 5-year ESKD risk was observed at week 56 (SRE: \u201312.84% [\u201316.65% to \u20139.03%];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), in conjunction with an expected rise in eGFR after drug washout. Subgroup analysis revealed larger relative lowering in 10-year CVD risk in those with CKD compared with those without (SRE: \u201311.3% versus \u20135.9%, and SDRN: \u201311.9% versus \u20136.1%, respectively; all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      <jats:sub>interaction<\/jats:sub>\n                      &lt; 0.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dapagliflozin improves estimated CVD and ESKD risk in participants with T1D, emphasizing the need for cardiorenal outcome trials in people living with T1D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.0000000641","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T12:19:05Z","timestamp":1738930745000},"page":"529-538","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Modeling Cardiorenal Protection with Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and DEPICT-2"],"prefix":"10.2215","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-6481","authenticated-orcid":false,"given":"Massimo","family":"Nardone","sequence":"first","affiliation":[{"name":"Department of Medicine, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-9253","authenticated-orcid":false,"given":"Luxcia","family":"Kugathasan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7947-1822","authenticated-orcid":false,"given":"Vikas S.","family":"Sridhar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritha","family":"Dutta","sequence":"additional","affiliation":[{"name":"Department of Applied Mathematics, University of Waterloo, Waterloo, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5570-3630","authenticated-orcid":false,"given":"David J.T.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Cardiac Sciences and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita T.","family":"Layton","sequence":"additional","affiliation":[{"name":"Department of Applied Mathematics, University of Waterloo, Waterloo, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Perkins","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Barbour","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2908-3324","authenticated-orcid":false,"given":"Tony K.T.","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-8401","authenticated-orcid":false,"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-8924","authenticated-orcid":false,"given":"Leif Erik","family":"Lovblom","sequence":"additional","affiliation":[{"name":"Biostatistics Department, University Health Network, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4781-4699","authenticated-orcid":false,"given":"Istvan","family":"Mucsi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4706-5170","authenticated-orcid":false,"given":"Remi","family":"Rabasa-Lhoret","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Faculty of Medicine, Montreal Clinical Research Institute, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria E.","family":"Rac","sequence":"additional","affiliation":[{"name":"Dalla Lana School of Public Health, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"Program for Health System and Technology Evaluation, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1033-8673","authenticated-orcid":false,"given":"Peter","family":"Senior","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-717X","authenticated-orcid":false,"given":"Ronald J.","family":"Sigal","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Cardiac Sciences and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Stanimirovic","sequence":"additional","affiliation":[{"name":"Dalla Lana School of Public Health, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"Program for Health System and Technology Evaluation, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6242-6638","authenticated-orcid":false,"given":"Frederik","family":"Persson","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3463-1102","authenticated-orcid":false,"given":"Elisabeth B.","family":"Stougaard","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3830-4304","authenticated-orcid":false,"given":"Alessandro","family":"Doria","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[{"name":"Department of Medicine, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"2","key":"B1-20250428","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2337\/dc14-0920","article-title":"Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study","volume":"38","author":"Khunti","year":"2015","journal-title":"Diabetes Care."},{"issue":"1","key":"B2-20250428","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-019-0953-7","article-title":"Risk of early mortality and cardiovascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide study","volume":"18","author":"Lee","year":"2019","journal-title":"Cardiovasc Diabetol."},{"issue":"7","key":"B3-20250428","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S2213-8587(22)00099-7","article-title":"Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0\u201314 years: a population-based retrospective cohort study","volume":"10","author":"Jansson Sigfrids","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"B4-20250428","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2337\/dc15-1990","article-title":"Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT\/EDIC study 30-year follow-up","volume":"39","year":"2016","journal-title":"Diabetes Care."},{"issue":"12","key":"B5-20250428","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s13300-021-01169-w","article-title":"Renal complications and duration of diabetes: an international comparison in persons with type 1 diabetes","volume":"12","author":"Dena","year":"2021","journal-title":"Diabetes Ther."},{"key":"B6-20250428","doi-asserted-by":"crossref","first-page":"2042018819863226","DOI":"10.1177\/2042018819863226","article-title":"Management of diabetes complications in youth","volume":"10","author":"Graves","year":"2019","journal-title":"Ther Adv Endocrinol Metab."},{"issue":"11","key":"B7-20250428","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"B8-20250428","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care."},{"issue":"9","key":"B9-20250428","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care."},{"issue":"9","key":"B10-20250428","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes Metab."},{"issue":"24","key":"B11-20250428","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med."},{"issue":"9","key":"B12-20250428","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care."},{"issue":"9","key":"B13-20250428","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care."},{"issue":"7","key":"B14-20250428","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.2337\/dc23-0129","article-title":"The effects of sotagliflozin in type 1 diabetes on clinical markers associated with cardiorenal protection: an exploratory analysis of inTandem3","volume":"46","author":"Sridhar","year":"2023","journal-title":"Diabetes Care."},{"issue":"12","key":"B15-20250428","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care."},{"issue":"1","key":"B16-20250428","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int."},{"issue":"10","key":"B17-20250428","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation."},{"issue":"22","key":"B18-20250428","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"2","key":"B19-20250428","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/dom.14248","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and-2 studies","volume":"23","author":"Phillip","year":"2021","journal-title":"Diabetes Obes Metab."},{"issue":"10","key":"B20-20250428","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","article-title":"Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials","volume":"8","author":"Groop","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"B21-20250428","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(19)30154-8","article-title":"SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"B22-20250428","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2337\/dc20-2586","article-title":"A validated prediction model for end-stage kidney disease in type 1 diabetes","volume":"44","author":"Vistisen","year":"2021","journal-title":"Diabetes Care."},{"issue":"11","key":"B23-20250428","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","article-title":"Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the steno type 1 risk engine","volume":"133","author":"Vistisen","year":"2016","journal-title":"Circulation."},{"issue":"7","key":"B24-20250428","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/dom.15047","article-title":"Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes","volume":"25","author":"Stougaard","year":"2023","journal-title":"Diabetes Obes Metab."},{"issue":"9","key":"B25-20250428","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00125-021-05478-4","article-title":"Development and validation of a cardiovascular risk prediction model in type 1 diabetes","volume":"64","author":"McGurnaghan","year":"2021","journal-title":"Diabetologia."},{"issue":"5","key":"B26-20250428","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation."},{"issue":"26","key":"B27-20250428","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med."},{"issue":"8","key":"B28-20250428","doi-asserted-by":"crossref","first-page":"108257","DOI":"10.1016\/j.jdiacomp.2022.108257","article-title":"Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines","volume":"36","author":"Stougaard","year":"2022","journal-title":"J Diabetes Complications."},{"issue":"4","key":"B29-20250428","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation."},{"issue":"8","key":"B30-20250428","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"7","key":"B31-20250428","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1159\/000524889","article-title":"Initial eGFR changes with ertugliflozin and associations with clinical parameters: analyses from the VERTIS CV trial","volume":"53","author":"Cherney","year":"2022","journal-title":"Am J Nephrol."},{"issue":"10","key":"B32-20250428","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2337\/dc19-0937","article-title":"The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes","volume":"42","author":"van Raalte","year":"2019","journal-title":"Diabetes Care."},{"issue":"10","key":"B33-20250428","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/dom.13811","article-title":"Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: the STOP DKA protocol","volume":"21","author":"Goldenberg","year":"2019","journal-title":"Diabetes Obes Metab."},{"issue":"23","key":"B34-20250428","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor","volume":"376","author":"Fralick","year":"2017","journal-title":"N Engl J Med."},{"issue":"8","key":"B35-20250428","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System","volume":"60","author":"Fadini","year":"2017","journal-title":"Diabetologia."},{"issue":"1","key":"B36-20250428","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/dc19-1481","article-title":"Use of sodium-glucose cotransporter 2 inhibitors in patients with type 1 diabetes and rates of diabetic ketoacidosis","volume":"43","author":"Hampp","year":"2020","journal-title":"Diabetes Care."},{"key":"B37-20250428","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.0000000540","article-title":"Efficacy and safety of sotagliflozin in patients with type 1 diabetes and CKD","author":"Sridhar","year":"2024","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B38-20250428","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care."},{"issue":"11","key":"B39-20250428","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1007\/s13300-020-00923-w","article-title":"Development and internal validation of a discrete event simulation model of diabetic kidney disease using CREDENCE trial data","volume":"11","author":"Willis","year":"2020","journal-title":"Diabetes Ther."},{"issue":"10","key":"B40-20250428","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","article-title":"SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study","volume":"66","author":"Anson","year":"2023","journal-title":"Diabetologia."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:55Z","timestamp":1786369375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000641","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"2024-08-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}